At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PLSE Pulse Biosciences
Trading 10-21 15:40:50 EDT
51.46
+0.62
+1.22%
High52.02Low50.07Vol230.52K
Open51.16D1 Closing50.84Amplitude3.84%
Mkt Cap3.67BTradable Cap1.06BTotal Shares71.32M
T/O11.86MT/O Rate1.12%Tradable Shares20.65M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Pulse Biosciences Collaborates With Clayman Thyroid Center on Thyroid Nodule Treatment
MT Newswires Live  ·  10-14
Pulse Biosciences Collaborates With Clayman Thyroid Center on Thyroid Nodule Treatment
Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
THOMSON REUTERS  ·  10-14
Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
Pulse Biosciences' 2027 Trial Readout Crucial to Evaluate New Pulsed Field Ablation Modality, Oppenheimer Says
MT Newswires Live  ·  10-14
Pulse Biosciences' 2027 Trial Readout Crucial to Evaluate New Pulsed Field Ablation Modality, Oppenheimer Says
Pulse Biosciences is Maintained at Outperform by Oppenheimer
Dow Jones  ·  10-13
Pulse Biosciences is Maintained at Outperform by Oppenheimer
Oppenheimer Adjusts Price Target on Pulse Biosciences to $60 From $35, Keeps Outperform Rating
MT Newswires Live  ·  10-13
Oppenheimer Adjusts Price Target on Pulse Biosciences to $60 From $35, Keeps Outperform Rating
Pulse Biosciences Inc. : Oppenheimer Raises Target Price to $60 from $35
THOMSON REUTERS  ·  10-13
Pulse Biosciences Inc. : Oppenheimer Raises Target Price to $60 from $35
Pulse Biosciences Issues Inducement Stock Options for 5,700 Shares to Two New Employees
Reuters  ·  10-10
Pulse Biosciences Issues Inducement Stock Options for 5,700 Shares to Two New Employees
Pulse Biosciences Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  10-10
Pulse Biosciences Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Pulse Biosciences nPulse Technology Featured at International Ventricular Arrhythmias Symposium 2026
Reuters  ·  10-08
Pulse Biosciences nPulse Technology Featured at International Ventricular Arrhythmias Symposium 2026
Pulse Biosciences Completes Enrollment in NANOPULSE-AF Trial
TIPRANKS  ·  10-07
Pulse Biosciences Completes Enrollment in NANOPULSE-AF Trial
Pulse Biosciences Hits 164-Patient Enrollment Target in Nanopulse-AF Pivotal Trial for nPulse AF Catheter System
Reuters  ·  10-07
Pulse Biosciences Hits 164-Patient Enrollment Target in Nanopulse-AF Pivotal Trial for nPulse AF Catheter System
Pulse Biosciences Achieves Enrollment Target in Nanopulse-Af Ide Pivotal Clinical Study Evaluating Npulse™ Cardiac Catheter System for Atrial Fibrillation Treatment
THOMSON REUTERS  ·  10-07
Pulse Biosciences Achieves Enrollment Target in Nanopulse-Af Ide Pivotal Clinical Study Evaluating Npulse™ Cardiac Catheter System for Atrial Fibrillation Treatment
Pulse Biosciences is Maintained at Buy by Canaccord Genuity
Dow Jones  ·  10-07
Pulse Biosciences is Maintained at Buy by Canaccord Genuity
Canaccord Genuity Sticks to Its Buy Rating for Pulse Biosciences (PLSE)
TIPRANKS  ·  10-06
Canaccord Genuity Sticks to Its Buy Rating for Pulse Biosciences (PLSE)
US Research Roundup-Affiliated Managers Group, Goldman Sachs, Vaxcyte
Reuters  ·  10-06
US Research Roundup-Affiliated Managers Group, Goldman Sachs, Vaxcyte
Pulse Biosciences Inc : Canaccord Genuity Raises Target Price to $58 from $43
THOMSON REUTERS  ·  10-06
Pulse Biosciences Inc : Canaccord Genuity Raises Target Price to $58 from $43
Pulse Biosciences management to meet with Oppenheimer
TIPRANKS  ·  10-02
Pulse Biosciences management to meet with Oppenheimer
Carvolix Appoints Anne Lange as Board Chair, Replacing Liane Teplitsky
Reuters  ·  09-30
Carvolix Appoints Anne Lange as Board Chair, Replacing Liane Teplitsky
Pulse Biosciences management to meet virtually with Freedom Capital
TIPRANKS  ·  09-24
Pulse Biosciences management to meet virtually with Freedom Capital
Pulse Biosciences initiated with a Buy at BTIG
TIPRANKS  ·  09-23
Pulse Biosciences initiated with a Buy at BTIG

Introduction

Company Name.
Pulse Biosciences
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. The company was incorporated in 2014 and is headquartered in Hayward, California.
Issue price:
--